| [1] |
Gao Y, Heller SL, Moy L. Male breast cancer in the age of genetic testing: an opportunity for early detection, tailored therapy, and surveillance[J]. Radiogranphics，2018，38(5)：1289-1311.
|
| [2] |
Johansson I, Killander F, Linderholm B，et al. Molecular profiling of male breast cancer - lost in translation? [J]．Int J Biochem Cell Biol, 2014，53：526-535.
|
| [3] |
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]．Nature，490(7418)：61-70.
|
| [4] |
Perou CM, Sorlie T, Eisen MB，et al. Molecular portraits of human breast tumours[J]．Nature，2000，406(6797)：747-752.
|
| [5] |
Johansson I, Nilsson C, Berglund P, et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker[J]. Breast Cancer Res, 2012，14(1)：R31.
|
| [6] |
Shaaban AM, Ball GR, Brannan RA，et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences[J]. Breast Cancer Res Treat，2012，133(3)：949-958.
|
| [7] |
Piscuoglio S, Ng CK, Murray MP，et al.The genomic landscape of male breast cancers[J]. Clin Cancer Res，2016，22(16)：4045-4056.
|
| [8] |
Sánchez-Muñoz A, Vicioso L, Santonja A. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes [J]. Mod Pathol, 2018，31(2)：299-306.
|
| [9] |
Cardoso F, Bartlett JMS, Slaets L，et al.Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program[J]. Ann Oncol，2018，29(2)：405-417.
|
| [10] |
Vermeulen MA, Slaets L, Cardoso F, et al. Pathological characterisation of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program[J]. Eur J Cancer, 2017，82：219-227.
|
| [11] |
Orr N, Lemnrau A, Cooke R，et al.Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk[J]．Nat Genet，2012，44(11)：1182-1184.
|
| [12] |
Johansson I, Ringnér M, Hedenfalk I. The landscape of candidate driver genes differs between male and female breast cancer[J]. PLoS One，2013，8(10)：e78299.
|
| [13] |
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013，24(9)：2206-2223.
|
| [14] |
AbdelJaoued S, Lhem B, Nasri M, et al.Prognostic implications of the intrinsic molecular subtypes in male breast cancer[J]. J BUON, 2017，22(2)：377-382.
|
| [15] |
Abreu MH, Afonso N, Abreu PH，et al. Male breast cancer: Looking for better prognostic subgroups[J]. Breast，2016，26：18-24.
|
| [16] |
Leone JP, Leone J, Zwenger AO，et al. Prognostic significance of tumor subtypes in male breast cancer: a population-based study[J]．Breast Cancer Res Treat, 2015，152(3)：601-609.
|
| [17] |
Nilsson C, Johansson I, Ahlin C, et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact[J]. Acta Oncol, 2013，52(1)：102-109.
|
| [18] |
Yu XF, Feng WL, Miao LL，et al. The prognostic significance of molecular subtype for male breast cancer: a 10-year retrospective study[J]. Breast, 2013，22(5)：824-827.
|
| [19] |
Kornegoor R, Verschuur-Maes, AH, Buerger H，et al. Molecular subtyping of male breast cancer by immunohistochemistry[J]. Mod Pathol, 2012，25(3)：398-404.
|
| [20] |
Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment[J]. Eur J Pharmacol, 2013，717(1/3)：71-83.
|
| [21] |
Chavez-Macgregor M, Clarke CA, Lichtensztaijn D, et al. Male breast cancer according to tumor subtype and race: a population-based study[J]．Cancer，2013，119(9)：1611-1617.
|
| [22] |
Zhu J, Davis CT, Silberman S，et al. A role for the androgen receptor in the treatment of male breast cancer[J]. Crit Rev Oncol Hematol，2016，98：358-363.
|
| [23] |
Humphries MP, Sundara RS, Honarpisheh H，et al.Characterisation of male breast cancer: a descriptive biomarker study from a large patient series[J]. Sci Rep, 2017, 7：45 293.
|
| [24] |
Cochrane DR, Bernales S, Jacobsen BM，et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide[J]. Breast Cancer Res，2014, 16(1)：R7.
|
| [25] |
Chen X, Liu X, Zhang L, et al. Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences[J]. Jpn J Clin Oncol，2013，43(10)：954-963.
|
| [26] |
Nilsson C, Holmqvist M, Bergkvist L, etal. Similarities and differences in the characteristics and primary treatment of breast cancer in men and women-a population based study(Sweden)[J]．Acta Oncol 2011，50(7)：1083-1088.
|
| [27] |
Yu E, Stitt L, Vujovic O，et al. Male breast cancer prognostic factors versus female counterparts with propensity scores and matched-pair analysis[J]. Cureus，2015，7(10)：e355.
|
| [28] |
van der Pol CC, Lacle MM, Witkamp AJ，et al.Prognostic models in male breast cancer [J]. Breast Cancer Res Treat，2016，160(2)：339-346.
|
| [29] |
Grenader T, Yerushalmi R, Tokar M, et al.The 21-gene recurrence score assay(Oncotype DX™)in estrogen receptor-positive male breast cancer：experience in an Israeli cohort[J]. Oncology，2014，87(1)：1-6.
|
| [30] |
Peethambaram PP, Hoskin TL, Day CN, et al. Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study[J]. NPJ Breast Cancer, 2017，3：41.
|